Category: Family

Hypoglycemic unawareness emergency care

Hypoglycemic unawareness emergency care

Cryer PE, et al. Executive Emegrency Program. Hypoglycekic control and severe dare following training in Sugar-Free Desserts, intensive Muscular endurance training plan therapy to unaareness Muscular endurance training plan freedom in people with type 1 diabetes: a prospective implementation study. As soon as the person is awake and able to swallow, offer a fast-acting carbohydrate such as glucose tablets or juice. Community Health Needs Assessment. Long-term follow-up evaluation of blood glucose awareness training. Key Messages It is important to prevent, recognize and treat hypoglycemic episodes secondary to the use of insulin or insulin secretagogues.

Hypoglycemic unawareness emergency care -

Your best bet is to practice good diabetes management and learn to detect hypoglycemia so you can treat it early—before it gets worse. Monitoring blood glucose, with either a meter or a CGM, is the tried and true method for preventing hypoglycemia.

Studies consistently show that the more a person checks blood glucose, the lower his or her risk of hypoglycemia. This is because you can see when blood glucose levels are dropping and can treat it before it gets too low. Together, you can review all your data to figure out the cause of the lows.

The more information you can give your health care provider, the better they can work with you to understand what's causing the lows. Your provider may be able to help prevent low blood glucose by adjusting the timing of insulin dosing, exercise, and meals or snacks.

Changing insulin doses or the types of food you eat may also do the trick. Breadcrumb Home Life with Diabetes Get the Right Care for You Hypoglycemia Low Blood Glucose. Low blood glucose may also be referred to as an insulin reaction, or insulin shock. Signs and symptoms of low blood glucose happen quickly Each person's reaction to low blood glucose is different.

Treatment—The " Rule" The rule—have 15 grams of carbohydrate to raise your blood glucose and check it after 15 minutes. Note: Young children usually need less than 15 grams of carbs to fix a low blood glucose level: Infants may need 6 grams, toddlers may need 8 grams, and small children may need 10 grams.

This needs to be individualized for the patient, so discuss the amount needed with your diabetes team. When treating a low, the choice of carbohydrate source is important. Complex carbohydrates, or foods that contain fats along with carbs like chocolate can slow the absorption of glucose and should not be used to treat an emergency low.

Treating severe hypoglycemia Glucagon is a hormone produced in the pancreas that stimulates your liver to release stored glucose into your bloodstream when your blood glucose levels are too low.

Steps for treating a person with symptoms keeping them from being able to treat themselves. If the glucagon is injectable, inject it into the buttock, arm, or thigh, following the instructions in the kit.

If your glucagon is inhalable, follow the instructions on the package to administer it into the nostril. When the person regains consciousness usually in 5—15 minutes , they may experience nausea and vomiting.

Do NOT: Inject insulin it will lower the person's blood glucose even more Provide food or fluids they can choke Causes of low blood glucose Low blood glucose is common for people with type 1 diabetes and can occur in people with type 2 diabetes taking insulin or certain medications.

Insulin Too much insulin is a definite cause of low blood glucose. Food What you eat can cause low blood glucose, including: Not enough carbohydrates. Eating foods with less carbohydrate than usual without reducing the amount of insulin taken. Timing of insulin based on whether your carbs are from liquids versus solids can affect blood glucose levels.

Liquids are absorbed much faster than solids, so timing the insulin dose to the absorption of glucose from foods can be tricky. The composition of the meal—how much fat, protein, and fiber are present—can also affect the absorption of carbohydrates. Physical activity Exercise has many benefits.

Medical IDs Many people with diabetes, particularly those who use insulin, should have a medical ID with them at all times. Hypoglycemia unawareness occurs more frequently in those who: Frequently have low blood glucose episodes which can cause you to stop sensing the early warning signs of hypoglycemia.

Have had diabetes for a long time. Tightly manage their diabetes which increases your chances of having low blood glucose reactions. Once recovered, regardless of the method used to increase serum glucose oral, IV, or liver glycogenolysis due to glucagon , the patient should continue to receive supplementation to prevent recurrence and reestablish glycogen stores as necessary.

If NPO, parenteral supplementation should continue to prevent hypoglycemia. If conscious and oral intake is possible, the patient should consume foods with longer-acting sources of energy complex carbohydrates, fats, proteins in order to prevent recurrence.

Pharmacists are well positioned to directly prevent, recognize, and treat hypoglycemia, and they can successfully develop institutional protocols and procedures and educate patients, caregivers, and other healthcare practitioners to achieve these goals. Treatment of hypoglycemia depends on the severity and setting, and ranges from self-treatment with oral administration of 15 g of simple carbohydrates to outpatient use of glucagon kits and from oral intake to parenteral dextrose or glucagon administration at an institution.

Pharmacist involvement in the care of patients at risk for hypoglycemia and in education on prevention, recognition, and treatment of hypoglycemia for patients and their close family members and associates is critically important in helping reduce complications and improve outcomes.

Seaquist ER, Anderson J, Childs B, Cryer P, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.

Diabetes Care. Minimizing hypoglycemia in diabetes. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med.

American Diabetes Association. Introduction: Standards of Medical Care in Diabetes— Seaquist ER, Miller ME, Bonds DE, et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD Study.

Service FJ, Cryer PE, Vella A. Hypoglycemia in adults: clinical manifestations, definition, and causes. Waltham, MA: UpToDate; Milligan PE, Bocox MC, Pratt E, et al.

Multifaceted approach to reducing occurrence of severe hypoglycemia in a large healthcare system. Am J Health Syst Pharm.

Maynard G, Kulasa K, Ramos P, et al. Impact of a hypoglycemia reduction bundle and a systems approach to inpatient glycemic management. Endocr Pract. Hypoglycemia low blood glucose. Accessed September 12, Precose acarbose package insert.

Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; March Glucagon: drug information. Accessed June 19, GlucaGen glucagon package insert. Plainsboro, NJ: Novo Nordisk, Inc; July Skip directly to site content Skip directly to search. Español Other Languages. Low Blood Sugar Hypoglycemia. Español Spanish Print.

Minus Related Pages. Have low blood sugar without symptoms? You may need to check your blood sugar more often. Causes of Low Blood Sugar There are many reasons why you may have low blood sugar, including: Taking too much insulin. Not eating enough carbs for how much insulin you take. Timing of when you take your insulin.

The amount and timing of physical activity. Drinking alcohol. How much fat, protein, and fiber are in your meal. Hot and humid weather. Unexpected changes in your schedule. Spending time at a high altitude. Going through puberty.

Symptoms of Low Blood Sugar How you react to low blood sugar may not be the same as how someone else with low blood sugar reacts. Common symptoms may include: Fast heartbeat Shaking Sweating Nervousness or anxiety Irritability or confusion Dizziness Hunger.

Hypoglycemia Unawareness. This is more likely to happen if you: Have had diabetes for more than years. Frequently have low blood sugar.

Throughout unawarrness day, depending on multiple factors, blood glucose Muscular endurance training plan called blood sugar levels Strategies for digestive wellness vary—up or down. This is normal. Unaareness if it Handheld blood glucose monitoring below the cae range and is Strategies for digestive wellness treated, it can get dangerous. Low blood glucose is when your blood glucose levels have fallen low enough that you need to take action to bring them back to your target range. However, talk to your diabetes care team about your own blood glucose targets, and what level is too low for you. Each person's reaction to low blood glucose is different.

Hypoglycemia or hypoglycemic unawareness is the emergencj to recognize early Muscular endurance training plan Professional head lice removal low blood sugar Energy Boost Tips they become Muscular endurance training plan.

When symptoms reach this stage, urgent treatment Antioxidant-Rich Stress Relief needed to prevent further Strategies for digestive wellness and life-threatening health problems, emergebcy as a dare or stroke. Emergencyy symptoms of low blood sugar include confusion, unawarenexs speech, unsteadiness when standing emergnecy walking, muscle twitching, and personality changes.

People with diabetes who tightly control their blood sugar Nutrition for cyclists are wmergency likely Hyppglycemic have episodes of low Hypoglycemid sugar. Frequent unwwareness severe low blood sugar episodes are likely to evolve into hypoglycemia unawareness.

The longer a person has had diabetes, the more likely it is that they will develop hypoglycemic unawareness. After a person has had one hypoglycemia unawareness episode, more are likely to occur. Author: Healthwise Staff. Medical Review: E. This information does not replace the advice of a doctor.

Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content. To learn more about Healthwise, visit Healthwise. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.

ca Network. It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again. Main Content. Important Phone Numbers. Top of the page.

Current as of: March 1, Author: Healthwise Staff Medical Review: E. Home About MyHealth. ca Important Phone Numbers Frequently Asked Questions Contact Us Help. About MyHealth. feedback myhealth. Include Images Large Print.

: Hypoglycemic unawareness emergency care

Hypoglycemia - Diabetes Canada The frequency of hypoglycemia among people with longstanding type 2 diabetes increases over time, as the body eventually stops making enough insulin. Modafinil is a dopamine reuptake inhibitor thus, it appears that dopamine signaling is potentially involved in the development of IAH. This can help you and your health care team identify patterns contributing to hypoglycemia and find ways to prevent them. Nurse 58 , — Leu, J. From to , there has been a trend in reduced hospitalizations for hyperglycemia, but the rates of hospital admissions for severe hypoglycemia remain almost two-fold higher than those for hyperglycemia Lipska et al.
Top bar navigation Improving patient self care using diabetes technologies. Unawarrness Strategies for digestive wellness on ejergency. Bmj Characterizing glycemic control and sleep in adults with long-standing type 1 diabetes and hypoglycemia unawareness initiating hybrid closed loop insulin delivery. COVID Dermatology Diabetes Gastroenterology Hematology. J Pediatr ;—
Addressing Hypoglycemic Emergencies Complications Muscular endurance training plan Unawreness Hypoglycemia Hypoglycrmic risks of hypoglycemia MRI imaging techniques the dangerous situations that can Hypoglyfemic while an individual is hypoglycemic, whether at home or at work e. Show the heart some love! UpToDate, Inc. Sepulveda, E. Quirós, C. Hypoglycemia in adults without diabetes mellitus: Clinical manifestations, diagnosis, and causes. Financial Assistance Documents — Florida.
Related Content

Self assessment quizzes are available for topics covered in this website. To find out how much you have learned about Diabetes Complications , take our self assessment quiz when you have completed this section.

The quiz is multiple choice. Please choose the single best answer to each question. At the end of the quiz, your score will display.

All rights reserved. University of California, San Francisco About UCSF Search UCSF UCSF Medical Center. Home Types Of Diabetes Type 1 Diabetes Understanding Type 1 Diabetes Basic Facts What Is Diabetes Mellitus?

What Are The Symptoms Of Diabetes? Diagnosing Diabetes Treatment Goals What is Type 1 Diabetes? What Causes Autoimmune Diabetes? To reduce the risk of severe hypoglycemia in people with diabetes, elucidating the mechanism behind IAH, as well as developing targeted therapies is currently an unmet need for those that suffer from IAH.

For people with diabetes, hypoglycemia is caused by excess insulin action in the setting of impaired counterregulation. In people who rely on insulin therapy to control their blood sugar levels, episodes of hypoglycemia increase the risk for subsequent episodes of hypoglycemia as part of a vicious cycle Cryer, ; Davis et al.

With recurrent episodes of hypoglycemia, brain glucose sensing becomes impaired and the usual neuronal signaling pathways that elicit a counterregulatory response to raise blood glucose levels are diminished Muneer, Thus, in the setting of impaired insulin and glucagon responses to hypoglycemia, recurrent hypoglycemia induces a syndrome of Hypoglycemia Associated Autonomic Failure HAAF that is composed of an impaired awareness of hypoglycemia IAH and a blunted counterregulatory response Davis et al.

The blunted counterregulatory response consists of impaired adrenergic signaling that results in an impaired endogenous epinephrine secretion from the adrenal medulla Muneer, In conjunction with reduced autonomic signaling, neurogenic symptoms of hypoglycemia are also attenuated.

Thus, people with recurrent episodes of insulin-induced hypoglycemia have a diminished ability to detect hunger, sweating, tremors, or other signals that indicate that carbohydrates should be ingested to raise blood glucose levels Cryer, ; Davis et al.

With better glycemic control, patients with Type 1 T1D and insulin-dependent Type 2 Diabetes T2D have been able to reduce the risk for diabetes complications e. Yet, as patients intensify glycemic control, the risk for iatrogenic hypoglycemia increases proportionately Holman et al. From to , there has been a trend in reduced hospitalizations for hyperglycemia, but the rates of hospital admissions for severe hypoglycemia remain almost two-fold higher than those for hyperglycemia Lipska et al.

Severe hypoglycemia is therefore a burden for patients with established diabetes and increases the risk of adverse clinical outcomes Mantovani et al. Severe hypoglycemia is also associated with impaired cognitive function Deary et al. Overall, hypoglycemia remains the rate-limiting factor in patients striving to achieve optimal glycemic control in people with Type 1 and longstanding Type 2 Diabetes Cryer, Nocturnal hypoglycemia is also prevalent in T1D.

Barnard et al. People with IAH often fail to wake from sleep to correct an episode of hypoglycemia due to their impaired activation of the autonomic nervous system in response to hypoglycemia Jones et al.

Another confounder in achieving optimal glycemic control is exercise Martyn-Nemeth et al. An bout of exercise increases glucose utilization and also increases tissue sensitivity to insulin.

This combination lowers blood glucose and increases the risk and incidence of hypoglycemia, compared to insulin alone Munoz et al. Moreover, antecedent exercise has been shown to blunt awareness and the counterregulatory response to hypoglycemia, thus contributing to the development of HAAF Galassetti et al.

Since HAAF increases the risk for severe hypoglycemia by fold Cryer, , it is important for healthcare providers to determine if their patients can sense hypoglycemia.

Several questionnaires have been developed to assist the diagnosis of IAH. The patient responds using a 7-point Likert scale where one to two denotes awareness, 3 is equivocal, and four to seven indicates unawareness Gold et al.

The Clark Score is a more multi-dimensional survey which consists of eight questions that are used to achieve objective answers regarding awareness of hypoglycemia Clarke et al.

With a score range from 0 to 7, a response total of 4 or above indicates IAH Clarke et al. The Pedersen-Bjergaard questionnaire asks patients to recall their previous experiences with hypoglycemia and asses their ability to recognize symptoms of hypoglycemia Pedersen-Bjergaard et al.

Since the IAH questionnaires vary, some discrepancies can arise such as overestimating impaired awareness in populations that may still have awareness intact, thus leading to the apparent failure of some studies to detect significant improvements in response to clinical interventions Sepulveda et al.

These questionnaires have been criticized for 1 having a high degree of inter-questionnaire variability in identifying subjects with IAH and subjects with impaired counterregulation, 2 susceptibility to recall bias by the subject, 3 lacking sensitivity to detect changes in hypoglycemia awareness over a short period, and 4 were developed in the pre-continuous glucose monitor CGM era excluding HypoA-Q.

Also, hypoglycemia questionnaires do not distinguish whether awareness reflects true restoration of hypoglycemia awareness i. Hypoglycemic questionnaires do have many meritorious qualities in that they are 1 inexpensive, 2 non-invasive, and 3 amenable to out-patient settings.

In addition, these questionnaires have been validated and adapted to populations beyond their original demographic Alkhatatbeh et al.

Added benefits for these questionnaires include them being flexible to meet a large sample size Sepulveda et al. More recent studies also demonstrate that patients with IAH diagnosed by questionnaires continue to experience higher risks of severe hypoglycemia Lin et al.

Mistimed or imprecise dosing of insulin increases the likelihood of hypoglycemic events and recurrent episodes of hypoglycemia lead to the development of IAH Cryer, ; Davis et al. In addition to people who have a history of hypoglycemic events, certain populations are at a greater risk for hypoglycemic episodes and IAH, such as the young, elderly, and those with comorbidities Munshi et al.

Thus, identifying individuals who are at a higher risk for severe hypoglycemia and IAH is a priority for clinical providers and their patients in order to decrease the incidence of both events. In spite of their limitations see above , the most practical method to assess for IAH in a clinical setting is hypoglycemia questionnaires.

However, if patients are not asked about hypoglycemia or fail to report asymptomatic hypoglycemia, the diagnosis of IAH can be missed Farrell and McCrimmon, Therefore, it is extremely important for providers to inquire about and for patients to be educated about IAH.

After identification of IAH, the goals would be to provide at-risk patients with strategies to recognize and avoid hypoglycemia. Prior to advanced diabetes technology such as CGMs and the automated insulin delivery systems, several of these earlier studies demonstrated that the scrupulous avoidance of recurrent episodes of hypoglycemia could restore at least partially awareness of hypoglycemia Cranston et al.

To the extent that HAAF may be reversed at least partially , avoidance of hypoglycemia is a practical goal treatment for IAH. Unfortunately, even with modern technology, complete avoidance of hypoglycemia is difficult, compounded by the evidence that only one to two episodes of hypoglycemia are sufficient to induce IAH Galassetti et al.

In the setting of intensive glycemic control achieved with intensive insulin delivery, complete avoidance of hypoglycemia may not be realistic for some individuals. The question remains whether complete avoidance of hypoglycemia using the latest strategies can restore hypoglycemia awareness.

Given the complexity of IAH, a variety of clinical treatment considerations have been investigated to decrease hypoglycemia and the cycle of IAH Figure 1.

In the following sections, various treatment options for IAH will be discussed see Table 1. FIGURE 1. Restoring awareness of hypoglycemia. While there is no direct treatment for impaired awareness of hypoglycemia IAH , there are therapies that can help avoid hypoglycemia, which include: education, pharmaceuticals, technology, and transplantation whole pancreas or islet cell.

Using these therapies, hypoglycemia can be avoided leading to improve sympathoadrenal responses of hypoglycemia and awareness of hypoglycemia. Strategies to avoid hypoglycemia include transplantation pancreas or islet cells , technology e. The overarching goal is to decrease incidences of hypoglycemia and thereby restore both awareness of hypoglycemia and improve the counterregulatory response to hypoglycemia.

Fundamentally, the most pressing issue with IAH is the inability to sense when blood glucose concentrations fall to severe levels i. Diabetes education programs have been successfully employed to improve glycemic control and the overall health of people with T1D and T2D Siminerio et al. Although not specifically designed to treat IAH, some of the original educational programs that focused on glycemic management resulted in improving hypoglycemia awareness.

The Diabetes Teaching and Treatment Program DTTP demonstrated in a year follow-up that the rates of hypoglycemia were reduced and the improvement in HbA1c was sustained after attending educational programs Plank et al.

Modeled after DTTP, the dose adjustment for normal eating DAFNE training program showed in a 1-year follow up that subjects had improved awareness of hypoglycemia and reduced rates of severe hypoglycemia Group, ; Hopkins et al.

Given the increased risk of hypoglycemia with intensive glycemic control, educational programs began to focus on improving awareness of hypoglycemia. More specific psychological training and bio-psycho-behavioral techniques have been shown to help people with diabetes improve their awareness.

The Blood Glucose Awareness Training Program BGAT is an IAH focused psychoeducational program Cox et al. Since its inception, BGAT has undergone several revisions as a result of multicenter trials across the globe. BGAT is available outside of a clinical setting, which enables it to reach more people and decrease the workload in the clinic Cox et al.

While still extremely effective at improving overall blood glucose awareness, BGAT did not intentionally set out to assess IAH. Nonetheless, several studies demonstrated the ability of BGAT in improving hypoglycemia awareness Cox et al. Adapted from BGAT, the HypoAware training program focused on training and empowering people with T1D and advanced T2D to reduce episodes of hypoglycemia, improve awareness, and reduce fear of hypoglycemia Rondags et al.

Another educational program for treating diabetic patients with hypoglycemia problems HyPOS , focused on optimizing intensive insulin therapy. Additionally, the long-term benefits of HyPOS curriculum remained after a month follow-up Hermanns et al. Similar to the HypoAware adaptation from BGAT, the dose adjustment for normal eating DAFNE —Hypoglycemia Awareness Restoration Training HART was developed from the DAFNE program.

The DAFNE-HART in a pre-post trial with 23 participants demonstrated that psychology plays an important in the development of IAH. Building on the DAFNE-HART program, the Hypoglycemia Awareness Restoration Programme for People with Type 1 Diabetes and Problematic hypoglycemia Persisting despite optimized self-care HARPdoc was developed as a multidisciplinary strategy targeting cognitive in subjects with IAH.

The HARPdoc program was recently evaluated and compared its effectiveness with BGAT in a population who continued to have IAH and developed recurrent severe hypoglycemia despite prior structured diabetes education and offered advanced diabetes technologies Jacob et al.

HARPdoc and BGAT were similarly able to improve awareness of hypoglycemia and decrease the rate and fear of hypoglycemia Jacob et al.

HARPdoc was also shown to decrease maladaptive hypoglycemia beliefs, diabetes distress and depression and anxiety symptoms which was not demonstrated in recipients of BGAT Jacob et al.

HARPdoc brain responses have also been compared to the HypoAware study Jacob et al. While limited in statistical power only compared 12 subjects , HARPdoc was able to determine awareness status more accurately during two-stepped hyperinsulinemic-hypoglycemic clamps Jacob et al.

In comparison to HypoAware, the HARPdoc treatment showed that the superior frontal gyrus region was more activated during hypoglycemia, indicating improved self-awareness and symptoms associated with hypoglycemia Jacob et al.

Treatment of IAH in people with T2D has been studied to a much lesser extent compared to studies in people with T1D. The Common Sense Model CSM assessed illness perceptions in subjects with T2D and IAH on insulin therapy Shen et al.

While the study showed that the overall welfare and coping of subjects was improved, CSM did not change fear or awareness of hypoglycemia Shen et al. These results may be due to a short-duration of follow-up 1 and 3-month.

The efficacy of educational programs cannot be understated. Educational programs that use close and frequent patient contact Cranston et al. For example, the HypoCOMPaSS trial Comparison of Optimized MDI versus Pumps with or without sensors in severe hypoglycemia Cox et al.

The positive effects of the HypoCOMPaSS program were maintained at least 2 years after the completion of the original study Speight et al. For people with IAH, hypoglycemia is often detected not by symptoms, but with glucose monitoring technology e.

Unquestionably, diabetes technologies have markedly improved treatment for people with diabetes Akturk and Garg, It is indeed unfortunate that the more widespread use of these valuable technologies is limited by socioeconomic inequalities Bellary et al.

Although these technological advances have unquestionably helped to improve glycemic control and reduce that incidence of severe hypoglycemia in people with T1D, the extent to which these technologies can restore awareness of hypoglycemia remains an active area of investigation Choudhary et al.

CGMs have revolutionized diabetes management. Since CGMs can measure glucose every 5 min and alert patients of impending low as well as high glucose levels, they represent a major leap forward in glycemic management over handheld glucometers.

While HbA1c has been the gold standard for assessing long-term glycemic control, the data available from CGMs are making these devices the new standard of care Battelino et al. CGMs indicate the amount of time subjects experience hypoglycemia and how often these episodes go unnoticed.

Henriksen et al. This study highlighted the persistent prevalence of IAH in people with T1D despite CGM usage. The Advanced Technologies and Treatments for Diabetes Congress formed a panel of expert individuals to compose CGM guidelines for clinician use Battelino et al.

To determine if these metrics would be useful in identifying individuals with IAH, Lin et al. showed that half of the subjects with IAH met the proposed guidelines for hypoglycemia Lin et al. Additionally, using CGM data, researchers proposed a new CGM metric to identify IAH.

One study assessed intermittent CGM use to identify risk factors for IAH and glycemic patterns Vieira et al. While CGM usage reduces the incidence and severity of hypoglycemic episodes, there are conflicting reports as to whether CGM usage results in an improved awareness of hypoglycemia.

A recent study Ali et al. Researchers found that after 3—4 months subjects decreased their TBR, which was associated with increased TIR and was sustained after 5—6 months Renard et al. Decreased TBR could improve awareness; however, this study found Renard et al. While CGM technology has made patients and clinicians more cognizant of the frequency of hypoglycemic events, it is clear that GCM use does not eliminate hypoglycemic episodes Lin et al.

Even a long-term study month of CGM use failed to improve both symptomatic responses to hypoglycemia and hormonal counterregulatory responses Rickels et al. Consistent with these disheartening findings, our research team has consistently found a persistently high prevalence of IAH among CGM users, again dispelling any notion that CGM usage somehow restores awareness of hypoglycemia Lin et al.

Alternatively, ineffective use of CGM hypoglycemia-informing features Lin et al. Identifying these and other factors that might be necessary for the restoration of hypoglycemia awareness are needed to develop mitigation strategies and achieve an overall goal of reducing the burden of disease in people with T1D.

In addition to CGMs, people with diabetes also use insulin pump delivery systems thus replacing multiple daily injections of insulin. The combination of CGM and insulin pump technologies have been described as the holy grail of diabetes management Templer, The CLS was developed by people with T1D and their families by creating an open-source software Templer, This software connects CGMs and insulin pumps to a software through a phone or computer, and analyzes blood glucose to make decisions that adjust insulin delivery Templer, Currently, there are three available platforms that combine a CGM and insulin pump: Loop, OpenAPS Open Source Artificial Pancreas , and AndroidAPS Android Artificial Pancreas.

However, as of yet, none of these platforms have been approved by the Federal Drug Administration Palmer et al. In this trial, subjects were randomized into a CLS or a sensor augmented pump SAP.

Hypoglycemia fear Cox et al. CLS subjects had improved hypoglycemia fear scores at 6 months and a tendency for improved confidence in managing hypoglycemia; however, awareness was not different between the technologies Kudva et al. With low or predicted low glucose values detected by CGM, sensor augmented pumps SAP allow for automated insulin suspension.

By temporarily suspending insulin delivery, SAP can avoid or limit the severity of hypoglycemia Steineck et al. SAPs have been shown to be useful in people with severe hypoglycemia Ly et al. The study reported a decrease in Hb1Ac, TAR, and Clarke scores; however, there was no change in TBR Takagi et al.

Thus, authors concluded that the SAP improved glycemic control by decreasing hyperglycemia and may improve awareness; but counterintuitively, not by reducing TBR Takagi et al. Given both 1 the limited evidence of improvement in awareness with SAPs, and 2 the rapid commercialization of automated insulin delivery systems, IAH research has evolved to be conducted with the next level of technology, automated insulin delivery systems.

AID systems have been shown to be effective in both T1D adults and adolescents in improving HbA1c, increasing TIR, and decreasing hypoglycemia Kovatchev et al. Malone et al. No statistical improvement for awareness was found; but there was a trend in improvement from baseline Malone et al.

Burckhardt et a l. While counterregulatory responses did not change epinephrine, norepinephrine, cortisol, growth hormone with the use of AID, the total symptom scores assessed both adrenergic and neuroglycopenic during a hypoglycemic clamp improved from baseline compared to subjects using a SAP alone Burckhardt et al.

In contrast to the Burckhardt study, Flatt et al. A score of 3 on the Clarke score is borderline for IAH; therefore, some aware subjects could have been included in the statistical analysis in the described study Nattero-Chávez et al.

Additionally, diabetes education provided to the AID subjects could have, independently, played a role in improving awareness scores Nattero-Chávez et al.

The benefits of automated insulin delivery cannot be minimized; the aforementioned studies showed improvements in glycemic management and awareness. It is worthwhile to note that while some intervention studies do demonstrate an improvement in hypoglycemia questionnaire scores, it is unclear if a statistical improvement is clinically relevant as study subjects often demonstrate a persistent impaired awareness of hypoglycemia Burckhardt et al.

It should be noted that the study design is another factor contributing to these seemingly discordant results viz-a-viz the ability of technology to restore awareness of hypoglycemia.

The putative factors that contribute to the short-term blunting of the sympathoadrenal response to hypoglycemia induced by a few bouts of antecedent hypoglycemia in non-diabetic subjects are almost certainly different from the factors that contribute to HAAF having developed over years in people with T1D.

Disparate patient inclusion criteria are also confounding factors when comparing results from different studies. These and other factors may explain the apparent efficacy of early studies showing benefits with short term one to three months interventions in small cohorts 6—12 subjects with T1D.

In contrast, recent interventions using the latest diabetes technologies failed to demonstrate an improvement in hypoglycemia awareness in larger cohorts Pratley et al. An alternative notion to the exclusively glucocentric etiology of HAAF, is the possibility that HAAF is a heterogeneous clinical entity that develops, in part due to recurrent hypoglycemia, but also develops due to other factors e.

If these heterogeneous factors are indeed major factors that contribute to HAAF, then perhaps the failure to restore awareness of hypoglycemia with novel diabetes therapeutics vide supra is not necessarily due to a failure to scrupulously avoid recurrent hypoglycemia.

Consequently, it is possible that multiple interventions addressing these many potential confounding variables may be necessary to completely restore normal awareness and counterregulation in all subjects. For people with intractable episodes of severe hypoglycemia, whole pancreas or islet cell transplantation remains an important treatment option recommended by the American Diabetes Association Robertson et al.

Previous studies have shown both whole pancreas and islet cell transplantation are effective almost immediately at restoring endogenous insulin and glucagon secretion Kendall et al. The authors concluded that either treatment would be most appropriate for patients with IAH Rickels et al.

Virtual elimination of hypoglycemia with intrahepatic islet transplantation in subjects with T1D leads to improvement in hypoglycemia symptom recognition Rickels et al. Following transplant, epinephrine response to hypoglycemia was improved at 6- months and normalized at months and the symptoms of hypoglycemia were normalized at both time-points after transplant Rickels et al.

Supporting the glucocentric cause of HAAF, findings in transplant patients indicate that the prolonged, near complete elimination of hypoglycemia, can completely reverse HAAF. The effects of various drugs on hypoglycemia awareness and counterregulatory responses have been assessed in preclinical models of HAAF, clinical models of inducible HAAF, and subjects with long-standing T1D and HAAF Summarized in Table 2.

With the goal of augmenting the response to hypoglycemia, pharmacological interventions have targeted sites of action that are responsible for blood glucose sensing. When blood glucose falls, neurons in the brain Thorens, and the periphery Fournel et al.

One peripheral glucose sensor that responds to hypoglycemia lies within the portal-mesenteric vein PMV Matveyenko et al. Recent studies suggest that PMV glucose sensing may be mediated via sodium-dependent glucose transporter 3 SGLT3 receptors.

Following antecedent hypoglycemia, miglitol Glyset © , Pfizer, New York, NY, United States a SGLT3 agonist, was shown to restore the counterregulatory response to hypoglycemia in rats Jokiaho et al.

The predominant glucose-sensing apparatus lies within the brain. Early studies identified the ventromedial hypothalamus VMH as a key glucose-sensing region Borg et al. In terms of testing responses to drug therapy, one study examined the effects of systemic and central VMH administration of a beta 2-adrenergic receptor agonist, formoterol, on the counterregulatory responses following hypoglycemia Szepietowska et al.

Systemic administration improved the glucose infusion rate and hepatic glucose production response to hypoglycemia; however, counterregulatory hormones did not change with formoterol administration Szepietowska et al.

While formoterol and miglitol improved counterregulation and hepatic glucose production of HAAF, awareness was not assessed in those studies and the effects of those drugs on IAH remain unknown.

In rodent models of HAAF, recurrent hypoglycemia consistently blunts the sympathoadrenal response noted by a blunted plasma catecholamine response Powell et al. Unfortunately, the ability to determine hypoglycemia unawareness induced by recurrent hypoglycemia has been understandably more difficult to quantify in animal models Sankar et al.

Of note, Farhat et al. As model of IAH, recurrent antecedent treatment with 2-deoxyglucose 2DG blunted the food intake response to insulin-induced hypoglycemia; yet rodents treated with carvedilol did not develop IAH i. Another area of the brain that has been implicated in glucose sensing is the perifornical hypothalamus PFH.

Researchers focused on the orexin-glucose-inhibited neurons in the PFH responsible for arousal as a target for IAH and explored treatment with the anti-narcolepsy drug, modafinil Teva Pharmaceutical Industries Ltd.

Mice underwent a conditioned place preference test surrogate test for IAH prior to recurrent hypoglycemia and treatment. Compared to saline-treated mice, modafinil-treated mice adjusted their preference for the food-associated chamber after insulin-induced hypoglycemia.

Additionally, researchers showed that modafinil restored glucose sensing by the orexin-glucose-inhibited neurons in the PFH Patel et al. Modafinil is a dopamine reuptake inhibitor thus, it appears that dopamine signaling is potentially involved in the development of IAH.

Consistent with this notion, metoclopramide Teva Pharmaceutical Industries Ltd. Based on these preclinical results, the potential of this drug to restore awareness of hypoglycemia in subjects with T1D and IAH has advanced to a Phase 2 clinical trial NCT Translation of these pre-clinical results to clinical trials remains an important step to validate potential drug therapies for the treatment of IAH.

Drugs that work within the adrenergic system seem like an obvious target that might improve both the counterregulatory response and awareness of hypoglycemia Cooperberg et al. Consistent with preclinical studies Li et al. Thus, some degree of adrenergic blockage within the CNS may serve to improve hypoglycemia awareness and hypoglycemic counterregulation, at least based on preclinical studies Farhat et al.

Another, similar pharmacological approach to treating IAH is targeting adenosine receptors to increase alertness and enhanced secretion of the counterregulatory hormones De Galan et al.

One study used theophylline, an adenosine-receptor antagonist, to determine its effects on IAH de Galan et al. In response to hypoglycemia, subjects with diabetes and IAH treated with theophylline demonstrated an improved counterregulatory hormone response but theophylline did not improve hypoglycemia symptom scores de Galan et al.

However, another methylxanthine, caffeine, was shown to stimulate more symptomatic hypoglycemic episodes i. The glucagon-like peptide-1 receptor agonist, exenatide, was used in a crossover trial in subjects with T1D and IAH van Meijel et al.

Subjects treated with exenatide for 4-week had no differences in frequency or time spent in hypoglycemia compared to the placebo group. Exenatide-treated subjects had similar symptom scores and counterregulatory hormone responses to that of the placebo group van Meijel et al.

A sodium-glucose cotransporter-2 inhibitor, dapagliflozin, has shown effectiveness van Meijel et al. Dapagliflozin treatment did not improve awareness of hypoglycemia, however, it did reduce the glucose infusion rates during the clamp indicating an improvement in glucoregulatory response to hypoglycemia van Meijel et al.

Using the same drug, another study assessed glucagon response in T1D subjects; however, subjects were on the lower end of the Clarke score median 3, range 1—5 , suggesting that awareness might have been present in some subjects.

Similar to previous results, dapagliflozin treatment did not improve counterregulatory hormone responses, symptom scores, or recovery from hypoglycemia Boeder et al. Treatment with the CNS stimulant, modafinil, resulted in improved autonomic symptom scores, higher heart rates, higher glucagon concentrations during hypoglycemia, and improved scores on cognitive tests; however, the epinephrine response was not altered Klement et al.

Since modafinil was administered in non-diabetic subjects, IAH was not present Klement et al. Conversely, another study also conducted in healthy subjects showed improvements in the norepinephrine response, but no other improvements in hormonal responses epinephrine, growth hormone, and cortisol or symptom scores during a hypoglycemic clamp Smith et al.

Both of these studies attribute the positive improvements seen in healthy subjects to γ-aminobutyric acid GABA signaling. Modulating GABA signaling as a means to restore counterregulation and hypoglycemia awareness is supported by pre-clinical models Chan et al. Clinically, antecedent GABA-A activation with the benzodiazepine, alprazolam, has been shown to blunt the neuroendocrine and autonomic nervous system responses to subsequent hypoglycemia in healthy humans Hedrington et al.

Consistent with these findings, antagonism of GABA with dehydroepiandrosterone DHEA can prevent the development of HAAF under experimental conditions in healthy humans Mikeladze et al. Thus, with successful proof of concept studies in healthy humans, more recent studies in people with long-standing diabetes have shown that GABA administration significantly augmented the hormonal counterregulatory response to hypoglycemia Espes et al.

Pre-treatment with opioid receptor agonists can impair the counterregulatory response to hypoglycemia Carey et al. Conversely, pre-treatment with the opioid receptor antagonist naltrexone can prevent the development of an impaired counterregulatory response to hypoglycemia Leu et al.

Based on animal studies that indicate a possible role for selective serotonin reuptake inhibitors SSRIs to augment the counterregulatory response to glucoprivation Baudrie and Chaouloff, , clinical studies have demonstrated that 6-week treatment with SSRIs augmented counterregulatory, but not symptom responses, to hypoglycemia in nondiabetic people Briscoe et al.

It remains to be determined if these beneficial effects of SSRIs are mediated by the inhibition of neuronal serotonin uptake or via inhibition of norepinephrine transport in the CNS Chaouloff et al.

It also remains to be determined why hypoglycemia awareness was not improved with SSRI therapy. IAH continues to be a complication in people with both T1D and T2D who seek optimal glycemic control with insulin therapy. Providers who care for patients with diabetes should inquire about hypoglycemia and IAH with a view towards considering treatment options.

This review shows that there are several advances in technology and educational approaches that can improve hypoglycemia awareness. With regards to pharmacological treatments, basic science research in animal models is continuing to elucidate the mechanism s responsible and these novel treatments for IAH are being advanced into clinical trials.

Future studies should focus on these possible mechanisms to develop more targeted therapies for patients who suffer from IAH.

EM: Writing—original draft. MD: Writing—original draft. YL: Writing—review and editing. MM: Writing—review and editing. MW: Writing—review and editing.

CM: Writing—review and editing. AW: Writing—review and editing. AM: Writing—review and editing. ZB: Writing—review and editing. BP: Writing—review and editing. LS: Writing—review and editing. AI: Writing—review and editing. SF: Writing—original draft.

NIH support DK, DK to SF, DK to YL, TL1TR to MD, as well as support from the University of Kentucky Barnstable Brown Diabetes Center and the Diabetes and Obesity Research Priority Area. The authors would like to thank and acknowledge NIH support DK, DK to SF, DK to YL, TL1TR to MD, as well as support from the University of Kentucky Barnstable Brown Diabetes Center and the Diabetes and Obesity Research Priority Area.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers.

Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Adachi, A. Convergence of hepatoportal glucose-sensitive afferent signals to glucose-sensitive units within the nucleus of the solitary tract.

PubMed Abstract CrossRef Full Text Google Scholar. Advani, A. Positioning time in range in diabetes management. Diabetologia 63 2 , — Aggarwal, S. Augmenting engraftment of beta cell replacement therapies for T1DM.

CrossRef Full Text Google Scholar. Agiostratidou, G. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American association of clinical endocrinologists, the American association of diabetes educators, the American diabetes association, the endocrine society, JDRF international, the leona M.

And harry B. Helmsley charitable trust, the pediatric endocrine society, and the T1D exchange. Diabetes care 40 12 , — Akturk, S. Technological advances shaping diabetes care. Alcantara-Aragon, V. Improving patient self care using diabetes technologies.

Ali, N. Fall in prevalence of impaired awareness of hypoglycaemia in individuals with type 1 diabetes. Alkhatatbeh, M. Impaired awareness of hypoglycemia in children and adolescents with type 1 diabetes mellitus in north of Jordan.

BMC Endocr. Amiel, S. Impaired awareness of hypoglycaemia. Diabetes 22 1 , S26—S A parallel randomised controlled trial of the Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia despite optimised self-care HARPdoc.

Skip directly to site content Skip directly to search. Español Other Languages. Low Blood Sugar Hypoglycemia.

Español Spanish Print. Minus Related Pages. Have low blood sugar without symptoms? You may need to check your blood sugar more often.

Causes of Low Blood Sugar There are many reasons why you may have low blood sugar, including: Taking too much insulin. Not eating enough carbs for how much insulin you take. Timing of when you take your insulin. The amount and timing of physical activity. Drinking alcohol.

How much fat, protein, and fiber are in your meal. Hot and humid weather. Unexpected changes in your schedule.

Spending time at a high altitude. Going through puberty. Symptoms of Low Blood Sugar How you react to low blood sugar may not be the same as how someone else with low blood sugar reacts. Common symptoms may include: Fast heartbeat Shaking Sweating Nervousness or anxiety Irritability or confusion Dizziness Hunger.

Hypoglycemia Unawareness. This is more likely to happen if you: Have had diabetes for more than years. Frequently have low blood sugar.

Frontiers | Current and future therapies to treat impaired awareness of hypoglycemia During the early stages of low blood glucose, you may:. Continuous glucose monitoring—derived data report—simply a better management tool. PubMed Abstract Google Scholar. Jama 13 , — RSkyler JS Ed. Given the direct action of insulin to increase cellular uptake and utilization of glucose, drugs that directly increase insulin concentrations as their primary mechanism of action are associated with the highest rates of hypoglycemia.


Amit Gupta : Hypoglycemia Unawareness and Management

Author: Maull

1 thoughts on “Hypoglycemic unawareness emergency care

  1. Ich empfehle Ihnen, auf die Webseite vorbeizukommen, wo viele Informationen zum Sie interessierenden Thema gibt.

Leave a comment

Yours email will be published. Important fields a marked *

Design by